The science of facial aging: what's happening below the skin.

01The two arrows of facial aging

The dermatology literature distinguishes between two broad categories of skin aging, and the distinction matters for understanding both what is happening and what to do about it.

Extrinsic aging (photoaging and exposure-driven aging) is what happens to skin from outside influences. The major drivers are UV exposure (the dominant contributor), smoking, pollution exposure, mechanical stress, harsh skin care practices, and inflammation from external sources. Extrinsic aging produces the classic features that aesthetic medicine targets most directly: pigmentation irregularities, fine lines layered over deeper lines, textural roughness, telangiectasias, elastosis, and the leathery quality of heavily sun-damaged skin.

Intrinsic aging is what happens to skin from inside the body. The major drivers are systemic biological processes that affect every cell in the body: oxidative damage, glycation, mitochondrial dysfunction, cellular senescence, hormonal changes, and chronic systemic inflammation. Intrinsic aging produces a more uniform pattern: progressive loss of dermal volume, fine wrinkling, thinning of the skin, loss of elasticity, and the general "tired" or "sagging" quality that no amount of topical treatment fully addresses.

In practice, these two arrows are not independent. They interact. UV exposure does not just damage skin externally - it also induces systemic inflammatory responses that feed back into intrinsic aging. Chronic systemic inflammation does not just affect intrinsic aging - it impairs the skin's ability to repair extrinsic damage and regenerate normally.

The visible face you see is the integrated output of both arrows.

02Why systemic inflammation drives visible aging

Among the biological drivers of intrinsic aging, chronic systemic inflammation is one of the most mechanistically central. The biology is worth understanding clearly.

The dermal compartment of skin is composed largely of collagen and elastin fibers, embedded in a matrix of glycosaminoglycans and supported by a network of dermal fibroblasts, immune cells, and capillaries. The health of this compartment depends on continuous coordinated activity of all of these elements: fibroblasts producing new collagen, balanced enzymatic remodeling of old collagen, immune surveillance without immune over-activation, adequate capillary perfusion.

Chronic systemic inflammation disrupts essentially every element of this system.

• Chronic immune activation increases the activity of matrix metalloproteinases (MMPs) - enzymes that degrade collagen and elastin. Over years, this shifts the dermal balance away from synthesis and toward degradation.
• Inflammatory cytokines impair fibroblast function, reducing the rate of new collagen production.
• Chronic oxidative stress, which accompanies chronic inflammation, damages dermal proteins directly through oxidative crosslinking and glycation.
• Inflammation alters capillary function and contributes to the microvascular changes (telangiectasias, perfusion irregularities) that are part of the aged appearance.
• Chronic inflammation accelerates cellular senescence in dermal cells, and senescent cells secrete a pro-inflammatory cytokine pattern that further amplifies local inflammatory load.

The result, over years, is the visible phenotype of intrinsic aging: thinning, sagging, loss of volume, loss of elasticity, fine wrinkling, and an overall less resilient skin.

This is not a controversial finding in dermatology research. The role of "inflammaging" in skin aging is now well-established in the literature. What is less commonly translated into aesthetic practice is the corollary: if you are not measuring and managing systemic inflammatory load, you are missing one of the central upstream drivers of the problem you are treating downstream.

03The connection between systemic biological age and facial aging

A reasonable next question: how strong is the empirical link between systemic biological aging and visible facial aging? Is it just mechanistic plausibility, or does the published research actually show that people with faster biological aging look older?

The literature does show this, and the connection has been studied in some interesting ways.

The Dunedin cohort, a longitudinal study following a New Zealand birth cohort over decades, has been one of the richest sources of data on biological aging. In studies from the Belsky group, the rate of biological aging measured by the DunedinPACE method has been correlated with facial age - people aging faster biologically appear visibly older for their chronological age, in standardized photographic assessments. The effect sizes are meaningful, and the relationship survives adjustment for many confounders.

Similar findings have emerged from other cohorts. Twins discordant for biological age tend to show visible facial differences. People with chronic inflammatory conditions tend to show accelerated facial aging. People who have made substantial lifestyle improvements often show visible facial improvement that tracks with their inflammatory marker improvements.

This makes biological sense. The face is not separately aging. It is participating in the same biology as the rest of the body. The face is, in many ways, the most observable readout of integrated systemic biology, because it is the part of the body we look at most.

04The lifestyle drivers of visible facial aging

If chronic inflammation is central to intrinsic facial aging, then the major lifestyle drivers of chronic inflammation are also major drivers of visible facial aging. This is not speculation; it is what the dermatology and biological aging literatures have converged on.

Smoking is, after UV exposure, probably the second most important environmental driver of facial aging. The mechanism is multiple: chronic systemic inflammation, direct vasoconstriction reducing dermal perfusion, oxidative damage, accelerated MMP activity. The visible signature of long-term smoking - perioral lines, leathery texture, dull complexion, accelerated elastosis - is recognizable to any experienced dermatologist.

Heavy alcohol consumption drives chronic inflammation, oxidative stress, dehydration, and direct vasodilatory changes. Long-term heavy drinking is associated with characteristic facial changes - capillary fragility, puffiness, accelerated volume loss - that align with the systemic inflammatory signature.

Poor sleep chronically elevates inflammatory markers including suPAR. The visible facial correlates - periorbital changes, dull complexion, accelerated fine line development - are well-recognized clinically.

Visceral adiposity drives chronic inflammation. The interaction with facial aging is complex (some volume in the face is desirable), but the systemic inflammatory drive from substantial visceral adiposity contributes to accelerated intrinsic aging.

Poor dietary patterns (high ultra-processed food intake, low fiber, inadequate antioxidant and omega-3 intake) elevate chronic inflammation. The facial correlates are subtle but real - diet quality is associated with skin appearance in multiple studies.

Chronic psychological stress drives sustained inflammatory activation. The facial signature of chronic stress - premature volume loss, accelerated fine line development, reduced complexion vitality - is recognized clinically and is consistent with the inflammatory mechanism.

The pattern across all of these is the same: the things that drive systemic chronic inflammation are the things that drive accelerated visible aging. They are the same biology.

05Where aesthetic medicine fits

We want to be careful here. We are not suggesting that aesthetic medicine should be replaced by systemic biological optimization. The two address different parts of the picture.

Aesthetic interventions - topicals, lasers, energy-based devices, injectables, surgical procedures - address the manifestation of aging and, in some cases, address some of the underlying biology. They have real value. They produce results that systemic biological optimization alone, on reasonable timeframes, will not match. The skill and judgment of the practitioner choosing and delivering these interventions is central to the visible outcome.

What systemic biological measurement adds is information about whether the upstream drivers of the problem are being addressed alongside the downstream manifestation. A patient who is getting excellent aesthetic treatment but whose chronic inflammatory load remains high is, in a real sense, fighting against their own biology. The aesthetic outcomes will be more durable, and the trajectory of intrinsic aging more favorable, when the upstream drivers are addressed in parallel.

This is the logic behind incorporating suPAR testing into aesthetic medicine practice. It is not a replacement for what aesthetic medicine does well. It is a complementary measurement that lets the practitioner and the patient understand whether the lifestyle context is supporting or undermining the aesthetic work.

For practitioners, this means a more complete clinical picture. For patients, it means understanding that aesthetic outcomes are co-determined by what they do between treatments - and having an objective way to track that.

06What does the patient relationship look like with this added?

In the most thoughtful aesthetic practices we work with, the integration of systemic measurement into the patient relationship plays out something like this:

The patient comes in for an aesthetic consultation. The practitioner does the usual comprehensive assessment - skin analysis, photographic baseline, discussion of concerns, treatment planning. As part of the broader picture, the practitioner introduces the concept that visible aging has both surface drivers and systemic drivers, and that an aesthetic practice that addresses only the surface will produce less durable outcomes than one that addresses both.

The practitioner offers a baseline suPAR measurement as part of the broader workup. The result is interpreted in the context of the patient's lifestyle, medical history, and aesthetic goals. The practitioner makes recommendations that combine aesthetic interventions with lifestyle conversations - sleep, alcohol, smoking, exercise, dietary patterns - where the patient's particular situation suggests opportunity.

Over the months and years of the patient relationship, both arrows are addressed. Aesthetic interventions are delivered on appropriate schedules. Lifestyle improvements are encouraged and tracked. Repeat suPAR measurements provide objective evidence of whether the lifestyle context is improving. The aesthetic outcomes are reinforced by, rather than fighting against, the patient's biology.

This is the integration that the best aesthetic clinicians have been moving toward for years. What systemic biological measurement adds is rigor - a clinically validated, objective marker that the lifestyle conversation is actually working.

07What to ask if you are evaluating this approach

For patients considering an aesthetic practice that incorporates systemic biological measurement:

• Does the practice integrate the measurement into the broader treatment plan, or treat it as a standalone product?
• Does interpretation happen with a qualified clinician who can have the lifestyle conversation rigorously?
• Is repeat measurement built into the protocol, or treated as a one-time output?
• Does the practice use a clinically validated biomarker, or a wellness-only product?
• Is the practitioner comfortable explaining what the marker does and does not measure?

The honest answers to these questions will tell you whether a given practice is genuinely integrating systemic biology, or just adding a test to the menu.

08Bottom line

Facial aging is the visible expression of systemic biology. The same chronic inflammatory drivers that drive long-term health risk also drive accelerated intrinsic aging of the face. Aesthetic medicine addresses the manifestation; systemic biological measurement and lifestyle optimization address the drivers. The combination is more powerful than either alone.

suPAR is a clinically validated biomarker of the chronic inflammatory load that contributes to both health risk and visible aging. It is not a replacement for aesthetic medicine - it is a complement to it. The aesthetic practices that integrate this thinking well are creating a more durable, more honest, and more clinically grounded form of aesthetic medicine.

That is the practice we are building Supar Health to support.